Yuchao Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuchao Chen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Zhenhua Dai
Section of Immunology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
3 shared publications Chun-Ling Liang
Section of Immunology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Joint Immunology Program, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510006, China
2 shared publicationsHuazhen Liu
Section of Immunology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Joint Immunology Program, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510006, China
2 shared publications- Bin Yang
Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester LE1 9HN, UK
1 shared publication Feifei Qiu
Section of Immunology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; Joint Immunology Program, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong 510006, China
1 shared publicationHaiding Huang
Immunology Program, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, China; The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, China
1 shared publication
Latest Publications
- 7 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 176, 116462
Α-Hederin alleviates psoriasiform skin inflammation by inhibiting NF-κB p65/CXCL2 Axis
- 7 March 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 176, 116462
Α-Hederin alleviates psoriasiform skin inflammation by inhibiting NF-κB p65/CXCL2 Axis
- 22 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 159, 114896
Immunoregulatory effects of traditional Chinese medicine and its ingredients on psoriasis
- 22 May 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 159, 114896
Immunoregulatory effects of traditional Chinese medicine and its ingredients on psoriasis
- Open Access
- 2 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 51
Roles for Exosomes in the Pathogenesis, Drug Delivery and Therapy of Psoriasis
Psoriasis is a chronic, recurrent and inflammatory skin disease. Although conventional immunosuppressants can ameliorate psoriatic symptoms, it tends to relapse over time. Previous studies have shown that exosomes from both immune and non-immune cells participate in psoriatic immunopathology. The biologically active cargoes in exosomes accelerate psoriasis progression by altering gene profiles and signaling pathways of neighboring cells. On the other hand, exosomes can be utilized as drug delivery platforms for psoriasis treatment. Especially, engineered exosomes may serve as drug delivery systems for effective delivery of proteins, nucleic acids or other drugs due to their low immunogenicity, good stability and ability to fuse with target cells. Therefore, investigation into the mechanisms underlying intercellular communications mediated by exosomes in skin lesions likely helps design drugs for therapy of psoriasis. In this review, we have summarized recent advances in the biogenesis of exosomes and their potential roles in the pathogenesis and treatment of psoriasis and further discussed their challenges and future directions in psoriasis treatment. In particular, this review highlights the immunoregulatory function of exosomes derived from immune or non-immune cells and exosome-based therapeutic applications in psoriasis, including their drug delivery systems. Thus, this review may help accelerate applications of exosomes for drug delivery and treatment of psoriasis.
- 2 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 51
Open AccessRoles for Exosomes in the Pathogenesis, Drug Delivery and Therapy of Psoriasis
Psoriasis is a chronic, recurrent and inflammatory skin disease. Although conventional immunosuppressants can ameliorate psoriatic symptoms, it tends to relapse over time. Previous studies have shown that exosomes from both immune and non-immune cells participate in psoriatic immunopathology. The biologically active cargoes in exosomes accelerate psoriasis progression by altering gene profiles and signaling pathways of neighboring cells. On the other hand, exosomes can be utilized as drug delivery platforms for psoriasis treatment. Especially, engineered exosomes may serve as drug delivery systems for effective delivery of proteins, nucleic acids or other drugs due to their low immunogenicity, good stability and ability to fuse with target cells. Therefore, investigation into the mechanisms underlying intercellular communications mediated by exosomes in skin lesions likely helps design drugs for therapy of psoriasis. In this review, we have summarized recent advances in the biogenesis of exosomes and their potential roles in the pathogenesis and treatment of psoriasis and further discussed their challenges and future directions in psoriasis treatment. In particular, this review highlights the immunoregulatory function of exosomes derived from immune or non-immune cells and exosome-based therapeutic applications in psoriasis, including their drug delivery systems. Thus, this review may help accelerate applications of exosomes for drug delivery and treatment of psoriasis.